Market revenue in 2023 | USD 283.0 million |
Market revenue in 2030 | USD 495.3 million |
Growth rate | 8.3% (CAGR from 2023 to 2030) |
Largest segment | Immunohistochemistry |
Fastest growing segment | Digital Pathology and Workflow |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Immunohistochemistry, In situ Hybridization, Primary & Special Staining, Digital Pathology and Workflow, Anatomic Pathology, Molecular Pathology |
Key market players worldwide | Roche Holding AG ADR, Abbott Laboratories, Thermo Fisher Scientific Inc, Siemens AG, Danaher Corp, BioMerieux SA, Qiagen NV, BD, Merck KGaA, GE Aerospace, Agilent Technologies Inc, Biogenex, Cell Signaling Technology, Bio SB, DiaGenic |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to tissue diagnostics market will help companies and investors design strategic landscapes.
Immunohistochemistry was the largest segment with a revenue share of 25.72% in 2023. Horizon Databook has segmented the Germany tissue diagnostics market based on immunohistochemistry, in situ hybridization, primary & special staining, digital pathology and workflow, anatomic pathology, molecular pathology covering the revenue growth of each sub-segment from 2018 to 2030.
According to German Cancer Research Center, about 45,000 individuals are estimated to be diagnosed with cancer every year. Large number of ongoing clinical trials in Germany related to anatomic pathology results in high uptake of anatomic and pathologic products and services, thereby supplementing market growth.
Furthermore, strategic initiatives undertaken by key players further boosts the market growth. For instance, in July 2021, QIAGEN and Sysmex Corporation signed a global strategic alliance for the development & commercialization of cancer companion diagnostics using next-generation sequencing and plasma-safe-seqS technology. Under this strategic alliance, QIAGEN will use ultrasensitive liquid biopsy applications in oncology.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany tissue diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Germany tissue diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account